165 results
Page 4 of 9
8-K
EX-99.1
6wig2ti9i351ld
3 Feb 21
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
8:36am
8-K
EX-99.1
zzfhbw4fogra 7bhoms
12 Nov 20
Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update
4:03pm
8-K
EX-99.1
1f4z2jq iaj
15 Sep 20
Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program
12:00am
8-K
EX-99.1
qgbfj
27 Aug 20
Vaxart Appoints Karen J. Wilson to its Board of Directors
8:09am
8-K
EX-99.1
cr7ctk9ixi77xhyqubdq
6 Aug 20
Vaxart Announces Second Quarter 2020 Results
4:07pm
8-K
EX-99.1
2ukdho6
13 Jul 20
Other Events
4:13pm
8-K
EX-99.1
dj4e2j 6ql1upukgzqfe
30 Jun 20
Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP
5:24pm
8-K
EX-99.2
37vs 037s
30 Jun 20
Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP
5:24pm
8-K
EX-99.1
2d495qs2xf6j
15 Jun 20
Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programs
5:25pm
8-K
EX-99.1
2vw fue4t0kifm12
12 May 20
Vaxart Announces First Quarter 2020 Financial Results
4:04pm
8-K
EX-99.1
hof0ux3a4t
29 Apr 20
Vaxart Announces Corporate Update for First Quarter 2020
12:00am
8-K
EX-99.1
95y2qp0bte57a53v b0
19 Mar 20
Vaxart Announces Fourth Quarter and Full Year 2019 Financial Results
4:04pm
8-K
EX-99.2
n763lc jdbxu
19 Mar 20
Vaxart Announces Fourth Quarter and Full Year 2019 Financial Results
4:04pm
8-K
EX-99.1
0b48y9 2iedivfh9
2 Mar 20
Vaxart Announces $10.0 Million Registered Direct Offering Priced At-the-Market
2:48pm